论文部分内容阅读
目的分析贝那普利与厄贝沙坦联合口服治疗对2型糖尿病合并高血压老年患者的血压控制及靶器官的保护作用。方法103例2型糖尿病合并高血压患者随机分两组,治疗组口服贝那普利10 mg.次-1.d-1,厄贝沙坦150 mg.次-1.d-1;对照组口服氨氯地平5 mg.次-1.d-1,吲达帕胺2.5 mg.次-1.d-1。疗程8周,监测血压每周2次,并记录出现的不良反应,用药前、后测尿微量白蛋白、血尿素氮、血肌酐、血尿酸、血常规和肝功能等指标。结果治疗8周后两组血压均有不同水平下降,总有效率差异无统计学意义;治疗组尿微量蛋白治疗前后差异有统计学意义(P<0.01),治疗后治疗组、对照组尿微量蛋白差异有统计学意义(P<0.01);治疗组血尿酸较前有所下降,对照组略有升高;其他指标均无显著变化。结论贝那普利与厄贝沙坦联合治疗有明显降压作用及降低尿中微量白蛋白和血尿酸,在对肾功能的保护方面优于氨氯地平联合吲达帕胺组。
Objective To analyze the effects of benazepril combined with irbesartan on blood pressure control and target organ in elderly patients with type 2 diabetes mellitus and hypertension. Methods A total of 103 patients with type 2 diabetes mellitus complicated with hypertension were randomly divided into two groups. The treatment group was given oral benazepril 10 mg once-1 d-1, irbesartan 150 mg once-1 d-1, and the control group Oral amlodipine 5 mg. Times -1.d-1, indapamide 2.5 mg. Times -1.d-1. The course of treatment was 8 weeks, the blood pressure was monitored twice a week, and the adverse reactions were recorded. Urinary albumin, blood urea nitrogen, serum creatinine, blood uric acid, blood and liver function were measured before and after treatment. Results After 8 weeks of treatment, the blood pressure in both groups decreased at different levels and the total effective rate was no significant difference. The urine microalbumin in the treatment group had significant difference before and after treatment (P <0.01) Protein difference was statistically significant (P <0.01); the treatment group serum uric acid decreased compared with the previous, slightly increased in the control group; other indicators had no significant change. Conclusion The combined treatment of benazepril and irbesartan has obvious antihypertensive effects and reduces urinary microalbuminuria and uric acid, and is superior to amlodipine and indapamide in protecting renal function.